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Rubella Immunization of Adult Females 
Using HPV-77 DK-12 Live Attenuated Rubella Virus 
Donald A. Romig, M.D.*, E . L , Quinn, M.D.*, 
Frank Cox, M.D.* and Robert G. Brackett, Ph.D.** 
This study demonstrates the serologic response as measured by the HAl test and the 
side reactions of the HPV-77 DK-12 live rubella vaccine in a small group of adult 
females. One hundred percent seroconversion was obtained using this vaccine. 
The mean titers obtained in two separate time periods post-vaccination are higher 
than those reported for several other rubella virus vaccines. A 66% occurrence of 
joint symptomatology was recorded post-vaccination with a mean duration of 11.6 
days; 24% of women who received placebo reported joint complaints which had a 
mean duration of 2.0 days. The difference between these two rates is somewhat 
greater than that reported for other HPV-77 strain vaccines and the average 
duration of these complaints is longer. The other symptoms reported post-
vaccination seemed insignificant when comparing both the placebo and the 
vaccine group. One woman became pregnant three months after vaccination and 
was subsequently therapeutically aborted. At the time of therapeutic abortion, 
attempts were unsuccessful to recover rubella virus from the products of con-
ception and cervical swabs. 
The U.S. Public Health Service Ad-
visory Committee on Immunization 
Practices^ and the Committee on Infec-
tious Diseases of the American Acad-
emy of Pediatrics currently recom-
mend that boys and girls from the age 
of one year through early elementary 
school years be vaccinated against 
rubella to eliminate the reservoir of 
susceptible children and to create a 
"herd immunity." In addition, this Ad-
visory Committee has made specific 
recommendations regarding live rubel-
*Infectious Diseases Division, Department 
of Medicine 
**Parke-Davis & Co., Detroit, Michigan 
la vaccination of the adult rubella-
susceptible female in the childbearing 
age. The study reported here was de-
veloped to show the serologic response, 
side-effects, safety and patient accept-
ability of live rubella immunization 
with HPV-77 DK-12 strain m a group 
of susceptible adult females. 
Materials and Methods 
One hundred and eighty adult fe-
males of childbearing age were screen-
ed for rubella sero-reactivity. The sub-
jects were from the staff, paramedical 
personnel and families of Henry Ford 
Hospital. Thirty-nine subjects (21.6%) 
were sero-negative. Subsequently, in 
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the summer of 1969, thirty of this 
latter group volunteered to be inocu-
lated with live attenuated rubella vac-
cine HPV-77 DK-12 in a reverse 
double blind study. The age range of 
the volunteers was from 14 to 27, with 
an average age of 21 years. This strain 
of rubella virus was safe and effective 
in trials with children- and was licensed 
for use in December of 1969. 
Before vaccination, each subject was 
interviewed and asked to afiirm that 
she was not pregnant. Each vaccinee 
was advised of the risk should she 
become pregnant within 90 days after 
vaccine administration and of the need 
to use an acceptable contraceptive 
measure—abstinence, oral contracep-
tive agents or an intrauterine device. 
The possibility of reactions, including 
transient arthritis, was explained to 
each volunteer. At the time of admis-
sion to the study, none had signs or 
symptoms of acute or chronic illness, 
a history of allergy to dogs or dog 
dander, or any known immunologic 
defect. None had received gamma 
globulin within the previous six weeks 
or a live virus immunization in the 
previous two weeks. 
Subjects were asked to record daily 
the presence or absence of the follow-
ing: sore throat, cough, running nose, 
burning or red eyes, earache, fever, 
headache, loss of appetite, rash, swol-
len glands, and joint pain. These ob-
servations were tabulated daily usuig 
a 70-day reporting form. The volun-
teers were advised that counseling and 
physician evaluation were readily avail-
able during the study period. 
Serum antibody titers were deter-
mined by modifications of the hemag-
glutination inhibition (HAI) method 
of Stewart.3 H A I tests were performed 
on all serum samples using the same 
lot of antigen by laboratory personnel 
who routinely perform several hundred 
assays weekly. 
Results 
Sero-reactivity. Table 1 shows the 
serologic response in 30 sero-negative 
adult females after administration of 
test vaccine. The number of subjects 
and the specific H A I titers are indicat-
ed for the time periods shown. One 
vaccine was not tested for serologic 
response in the first time period but 
was in the second. Another subject 
withdrew from the study after her first 
inoculation and bleeding. She refused 
to complete the second half of the 
study. She was tested in the first time 
period but not the second. The geo-
metric mean titers for the first and 
second study periods were 1:137 and 
1:232 respectively. Seroconversion in 
this study was 100%. 
The mean titers obtained with HPV-
77 DK-12 vaccine in this study are 
higher than those reported for the 
other licensed rubella vaccines. Hilde-
brandt and Weber-* found adult females 
had a mean H A I titer of 1:498 be-
tween days 44 and 74 post-immuniza-
tion with the Cendehill-51 strain. With 
the same strain Halstead et aP reported 
titers of 1:80 at 35 days. Lerman," 
studying the HPV-77 DE-5 strain in 
adolescent girls and young women, 
found a titer of 1:42 had developed 56 
days after receipt of vaccine. Weibel 
et al" reported titers of 1:53 in women 
42 days after the duck embryo vaccine. 
Studies with the RA 27/3 vaccine 
strain recently licensed in England 
showed seroconversion by either the 
subcutaneous or intranasal inoculation; 
however, titers lower than those in this 
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Table I 
SEROLOGIC RESPONSE IN 30 SERONEGATIVE ADULT 
FEMALES GIVEN RUBELLA HPV-77 DK-12 VACCINE 
Number Of Subjects 
HAI Titer 0 Days 
(Prevaccination) 
32-63 Days 
after vaccination 
70-120 Days 
after vaccination 
<1:4 30 0 0 
1:4 0 0 0 
1:8 0 D 0 
1:16 0 0 c 
1:32 0 3 0 
1:64 c 7 c 
1:128 0 4 7 
1:256 0 14 4 
1:512 0 1 3 
1:1024 0 0 1 
TOTAL NO 
SUBJECTS 30 29 15 
GEOMETRIC 
MEAN TITER < 1:4 1:137 1:232 
study were recorded at 5 and 17 
months post-vaccination.* 
Side Reactions. The clinical findings 
in the vaccine and placebo groups are 
compared in Table I I . The total days 
of observation (cf 1163 vs 1203) in 
both groups are similar. Joint involve-
ment was the only clinical finding 
which was significantly different (p = 
0.001 in the Chi square test). Although 
the occurrence of headache is not sig-
nificant statistically, a definite cluster of 
headaches appeared in subjects receiv-
ing the live vaccine between day 11 and 
14. No other clinical finding had a 
temporal relationship to vaccine ad-
ministration except for joint com-
plaints. 
In comparing the subtotals obtained 
after eliminating joint complaints, there 
is no statistically significant difference 
between the two groups in the number 
of episodes of the various complaints. 
Arthritis and/or Arthralgia. Table 
I I I summarizes the reported joint 
symptoms in the vaccinees and placebo 
subjects. During the course of this 
study, subjects who recorded joint 
pains were not always seen by a physi-
cian. Accordingly, the tabulations were 
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Table II 
COMPARISON OF CLINICAL FINDING IN PLACEBO AND VACCINE SUBJECTS 
T 
Placebo Vaccine 
No. of 
Episodes 
Average 
Duration 
No. of 
Episodes 
Average 
Duration 
Sore Throat 12 2.66 15 2.33 
Cough 6 2.66 10 4.1 
Earache 3 1.0 1 1.0 
Running Nose 8 4.25 10 4.5 
Eyes Burning or Red 2 1.0 4 2.75 
Fever 2 1.5 8 2.25 
Headache 22 1.47 27 2.03 
Appetite Loss 5 2.4 6 3.16 
Rash 3 2.33 2 2.5 
Swollen Glands 4 1.5 6 3.16 
Subtotal 67 2.1 89 2.79 
Joint Pain (including Back) r 2.8 31* 7.22 
TOTAL 
Day of Observation 1163 1203 
*_P value = 0.001 by Chi square 
made without attempts at delineating 
arthritis from arthralgia. 
Sixty-six percent of the vaccinees re-
ceiving HPV-77 DK-12 rubella vmis 
experienced joint discomfort as com-
pared to 24% of the placebo subjects. 
These percentages include five indi-
viduals who experienced back pain 
during the study period. 
Table I I I compares the vaccine and 
placebo groups as to time of onset and 
duration of joint symptoms. The time 
of onset in our study is similar to that 
obtained by Weibel^ and Lerman et aF 
using HPV-77 DE-5 vaccine. The 
mean duration with the study vaccine 
is greater than they report for the 
HPV-77 DE-5 live rubella vaccine. If 
one adjusts the time of onset of arthri-
tic symptoms reported after natural 
disease'' !" s^ "day after the onset of 
rash" to compensate for the incubation 
period, the mean time of onset approxi-
mates that found with the vaccine in-
duced symptoms, 20.7 days. However, 
the mean duration of 3.5 days^ " and 
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Table III 
ARTHRITIS OR ARTHRALGIA IN 30 ADULT FEMALES 
GIVEN RUBELLA VACCINE HPV-77 DK-12 
Number with arthralgia or arthritis/ 
Number observed 
Time of onset: 
Range 
Mean 
Duration: 
Range 
Mean 
Vaccine 
20/ 
30 
12-31 days 
20.7 days 
1-29 days 
11.6 days 
Placebo 
7/ 
29* 
1-54 days 
22.5 days 
1-5 days 
2 days 
*One subject withdrew from study and did not receive placebo. 
9 days" is less than the 11.6 days which 
we observed. The persistence of joint 
discomfort with natural rubella is ap-
parently quite variable, 1-7 days^ " to 
1-28 days* with the latter similar to 
our finding of 1-29 days. 
The sites of joint involvement are 
shown in Table IV. Of the 20 subjects 
who reported joint complaint, 12 
(60%) did not specify location or 
potential multiple sites of joint involve-
ment. These 12 vaccinees were not 
examined by one of the investigators, 
so we can conclude little except to 
suggest that duration and/or extent of 
joint involvement was not significant 
enough to warrant the attention of a 
physician. However, the remainder of 
the data shows 17 separate sites of 
joint involvement in eight individuals, 
ie, 26.6% of the vaccinees. If back 
discomfort is eliminated from these 
tabulations, then 16 sites of involve-
Table IV 
SITES OF JOINT INVOLVEMENT IN 20 
VACCINEES WITH RUBELLA ARTHRITIS OR ARTHRALGIA 
Hand 
Proximal interphalangeal 
Fingers 
Wrist 
Foot 
Metatarsophalangeal 
Toes 
Hip 
Knee 
Ankle 
Back 
Joint not specified 
Total 
?. 
3 
1 
1 
2 
1 
3 
1 
3 
12 
29 
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ment were recorded in seven subjects. 
Seven of the placebo subjects (24%) 
also experienced joint symptoms as 
seen in Table I I I . The mean duration 
of joint symptoms in the placebo group 
is much less than that in the vaccine 
group. In naturally-occurring rubella 
as described by Yanez,'-' there was no 
documented involvement of the spine 
or axial-skeleton. Neither did Thomp-
son et al- find axial-skeletal involve-
ment among 40 carefully studied 
children with joint symptoms following 
immunization with HPV-77 DK-12. 
However, Smith and Guzowskai" re-
ported 20% of their patients with 
natural rubella exhibited spine dis-
comfort, 8% of them experiencing 
spinal stiffness. Because of this report, 
back discomfort must be considered as 
a possible clinical finding following 
natural or vaccine induced rubella in-
fection. The sites of joint involvement 
in naturally-occurring rubella arthritis 
are similar to those noted in this study, 
the symptoms prepondering in the 
small joints of the hands and feet. 
Tenosynovitis, which has been re-
ported by Thompson et al- and Yanez 
et al,» did not appear to contribute to 
the joint or musculo-skeletal symptoms 
of this vaccine group. Since we re-
corded only one subject with wrist in-
volvement during the study, tenosyno-
vitis was not a prominent feature. 
Significant joint involvement after 
rubella vaccination has been reported 
by several other investigators. The 
evaluation by Halstead et al" has shown 
that the Cendehill vaccine in adult 
women produced very few joint symp-
toms. Other studies tend to support 
this finding.** !' However, the HPV-77 
DE-5 live rubella strain has been 
shown to produce joint complaints in 
39 to 43% of susceptible women vac-
cinated.*'** While minimal swelling was 
noted in the fingers of one subject and 
the knee of another, no significant ef-
fusions were observed as have been 
reported with HPV-77 DE-5' and 
Cendehill." 
Complications 
One of the vaccinees became preg-
nant three months after vaccination. 
She was using an intrauterine device at 
the time of conception. As fetal trans-
mission of the vaccine virus has been 
reported by other investigators,'- thera-
peutic abortion was performed 131 
days after live rubella virus vaccine and 
approximately 41 days after concep-
tion. The estimated day of conception 
occurred at 90 days after vaccine ad-
ministration. Two different laboratories 
unsuccessfully attempted rubella virus 
isolation from the decidual tissue and 
cervical swabs obtained at the time of 
therapeutic abortion. 
Discussion 
There is a lack of unanimity regard-
ing mass immunization of prepubertal 
children as an indirect approach to the 
elimination of rubella virus risk to the 
fetus. Critics of this approach have 
been concerned with effectiveness of 
the "herd immunity concept" in pre-
venting rubella disease, reinfection of 
vaccinees on exposure to wild virus, 
spread of potentially teratogenic at-
tenuated virus from child to pregnant 
mother, and the duration of immun-
ity, la-is 
An alternative prophylactic ap-
proach is the direct immunization of 
postpubertal females. The major con-
cern here lies in the as yet incompletely 
assessed risk of attenuated vaccine 
virus infection of the fetus. Should the 
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women be pregnant at the time of 
vaccination or become pregnant within 
one or two months, will the virus infect 
and damage the fetus? Data on this 
subject is still limited but Vaheri et alp-
has reported on the isolation of rubella 
virus from uterine products at the time 
of hysterectomy or curettage after ru-
bella vaccine administration to preg-
nant women. Similarly Phillips et al"' 
recently described the isolation of ru-
bella virus from decidual tissue ob-
tained at eight weeks of gestation ap-
proximately 37 days after vaccination. 
Histological changes in the tissue were 
described as similar to those seen in 
gestational rubella. 
Another concern regarding rubella 
immunization, which applies to the 
immunization of children as well as 
women of childbearing potential, is the 
matter of reinfection. Horstman et a l " 
reported a reinfection rate of 80% in 
Cendeh ill-vaccinated young adult males 
exposed in an epidemic based on a 
four-fold or greater increase in hemag-
glutination-inhibiting and complement-
fixing antibody. This she compares to 
a 3.4% response in naturally immune 
men in the same recruit population. 
The evidence she presents indicates 
that "reinfection rates are correlated 
in a general way with H A I antibody 
levels." This is supported by data from 
Abrutyn et al-" in their 9-month fol-
low-up on vaccinated children exposed 
to natural challenge. They found rein-
fection rates of 11.6% for placebo 
recipients, 13.1% for HPV-77 DE-5 
vaccinees and 4.4% for HPV-77 DK-
12 vaccinees. They propose that re-
infection occurred less frequently 
among the HPV-77 DK-12 recipients 
because of the generally higher titer 
induced by this vaccine. 
The hazard of reinfection occurring 
in a pregnant woman with vaccine in-
duced immunity is significant only if 
viremia occurs. Data available to date 
has failed to show that viremia occurs 
during reinfection.-' However, virus 
shedding from the pharynx of rein-
fected vaccinees has been reported to 
occur but at a much reduced rate when 
compared to natural infection.'^'^^ 
Conclusions 
1. An attenuated live rubella virus 
vaccine, HPV-77 DK-12, yielded 
100% seroconversion and antibody 
titers higher than reported for other 
currently available rubella vaccines. 
2. The clinical findings of joint in-
volvement after vaccine administration 
were significantly greater than after 
placebo administration. The percentage 
of subjects that experienced joint symp-
toms in this study was greater than that 
reported with other currently available 
rubella vaccines. 
3. Prestudy counselling may have 
conditioned some responses. However, 
no subject regretted her participation 
in the study. This positive response 
despite the occurrence of joint symp-
tomatology was gratifying. 
4. Fetal transmission was not docu-
mented in one subject who became 
pregnant three months after vaccine 
administration. 
5. The practice of immunizing wom-
en of childbearing potential is a matter 
for serious consideration and must be 
evaluated on an individual basis by 
the physician and patient. Every effort 
should be taken to insure against im-
munizing a pregnant woman or one 
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